Arcellx Inc (ACLX) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Arcellx Inc   (NASDAQ: ACLX)

Arcellx Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Arcellx Inc in the fourth quarter 2025?
Arcellx Inc recorded a cumulative net loss of $-229 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -55.42%.

Within the Biotechnology & Pharmaceuticals industry 59 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 2960 to 3454.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -11.53 % -8.75 % -19.49 % -16.04 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -229 -218 -188 -162 -107
Return On Equity (TTM) -55.42 % -51.13 % -43.04 % -35.27 % -22.35 %
ACLX's Total Ranking # 3454 # 2960 # 2120 # 2177 # 1939
Equity (TTM) in Millions 402 441 392 417 455
Seq. Equity Change -8.72 % 12.38 % -5.92 % -8.33 % -5.84 %
Seq. Net Income Change - - - - -

Back to ACLX Management Effectiveness >> ACLX's 5 Years Annual ROE >> Compare ACLX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 60
Sector # 460
Overall # 3454

Return On Equity Statistics
High Average Low
-8.28 %
-40.63 %
-76.02 %
(Sep 30 2024)   (Dec 31 2022)





ACLX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022
Total Equity in Millions 402 455 485 205 0
Y / Y Equity Change -11.53 % -6.3 % 136.82 % - -
Net Income in Millions -229 -107 -71 -189 0
Y / Y Net Income Change - - - - -
Return On Equity -56.9 % -23.6 % -14.56 % -92.06 % -

Back to ACLX Management Effectiveness >> ACLX's 5 Years Annual ROE >> Compare ACLX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ACLX's' Return on Equity at Yahoo Finance
ACLX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ACLX's Competitors
Subscribers only: Roe for Arcellx Inc 's Suppliers
Subscribers only: Return On Equity for ACLX's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.